Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filings
MORE TOOLS
WatchlistUnusual buyingGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreUnusual buyingGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View TRAW insider activity ↗

TRAWTraws Pharma, Inc.

THE LATEST REPORTED YEAR

The company reported a profit.

$9.17M net income for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$2.79MYear ended December 31, 2025
Profit or loss$9.17MYear ended December 31, 2025
Cash from the business-$18.19MYear ended December 31, 2025
Total assets$11.47MAs of June 30, 2026
Total liabilities$9.78MAs of June 30, 2026
Cash & equivalents$20.56MAs of December 31, 2023
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$1.23M
2018-12
$2.18M
2019-12
$231K
2020-12
$226K
2021-12
$226K
2022-12
$226K
2023-12
$226K
2024-12
$2.79M
2025-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2025 – December 31, 2025$2,790,000April 15, 202610-K ↗
January 1, 2024 – December 31, 2024$226,000April 15, 202610-K ↗
January 1, 2023 – December 31, 2023$226,000March 31, 202510-K ↗
January 1, 2022 – December 31, 2022$226,000April 1, 202410-K ↗
January 1, 2021 – December 31, 2021$226,000March 30, 202310-K ↗
January 1, 2020 – December 31, 2020$231,000March 21, 202210-K ↗
January 1, 2019 – December 31, 2019$2,183,000March 18, 202110-K ↗
January 1, 2018 – December 31, 2018$1,228,000March 27, 202010-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:Revenues · Retrieved October 13, 2026

Response SHA-256: c7aad4bae6948c123e86432faae3c4936a66036b64d2dcc75cc144be1c1002e5

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.